Scarica l'app Stockscreener
1.08
0.92%
-0.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Biovie Inc Borsa (BIVI) Ultime notizie
New to The Street Announces Upcoming Bloomberg Air Dates Featuring FLOKI, BioVie Pharmaceuticals, Beeline, Arrive AI, and Commercialville - The Oklahoman
Northern Trust Corp Buys Shares of 16,878 BioVie Inc. (NASDAQ:BIVI) - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIVI - ACCESS Newswire
The Law Offices of Vincent Wong Remind BioVie Investors of a Lead Plaintiff Deadline of March 19, 2024 - marketscreener.com
BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Lohud
Investors' Lawsuit Against BioVie Moves to Evidence Review — Here's How to Recover Losses - TradingView
Transcript : BioVie Inc.Special Call - marketscreener.com
BioVie (NASDAQ:BIVI) Trading 1.9% Higher – Time to Buy? - Defense World
FY2025 EPS Estimates for BioVie Raised by Analyst - Defense World
BioVie Inc. Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - marketscreener.com
BioVie (BIVI) Begins Phase 2 Trial for Long COVID Treatment | BI - GuruFocus
BioVie (BIVI) Begins Phase 2 Trial for Long COVID Treatment | BIVI Stock News - GuruFocus
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial - GlobeNewswire
New Long COVID Treatment Hope: BioVie Launches Phase 2 Trial for 20M+ US Patients with Brain Fog - Stock Titan
BioVie (BIVI) To Host Key Opinion Leader Event Discussing Parkin - GuruFocus
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of - GuruFocus
BioVie to host KOL event on Phase 2 study of bezisterim - TipRanks
BioVie Inc. to Host Virtual KOL Event Discussing Parkinson’s Disease and Update on Phase 2 SUNRISE-PD Trial for Bezisterim - Nasdaq
BioVie to Host Virtual KOL Event to Discuss the Phase 2 - GlobeNewswire
Biovie Inc. to Host Virtual Kol Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 - marketscreener.com
Critical Survey: Coya Therapeutics (NASDAQ:COYA) vs. BioVie (NASDAQ:BIVI) - Defense World
BIOVIE Earnings Results: $BIVI Reports Quarterly Earnings - Nasdaq
BIOVIE INC. SEC 10-Q Report - TradingView
Lost Money on BioVie Inc.(BIVI)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
BioVie (BIVI) to Release Quarterly Earnings on Tuesday - Defense World
Investors who lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
BioVie Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before March 19, 2024 to Discuss Your RightsBIVI - ACCESS Newswire
Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIVI - ACCESS Newswire
Investors who lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024BIVI - ACCESS Newswire
Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
INVESTOR ALERT: Potential Recovery for BioVie Inc. (BIVI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Shareholders that lost money on BioVie Inc. (BIVI) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class ActionBIVI - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out - ACCESS Newswire
BioVie to Present Rationale and Design of Phase 2 - GlobeNewswire
BioVie (BIVI) Showcases Parkinson's Trial at Global Conference | BIVI Stock News - GuruFocus
Market Insights: BioVie Inc (BIVI)’s Notable Gain of 1.75, Closing at 1.16 - DWinneX
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025) - TradingView
BioVie (BIVI) Establishes Influential Corporate Advisory Board | - GuruFocus
BioVie assembles advisory board for neurodegenerative care By Investing.com - Investing.com Canada
BioVie (BIVI) Establishes Influential Corporate Advisory Board | BIVI Stock News - GuruFocus
BioVie assembles advisory board for neurodegenerative care - Investing.com
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth - The Manila Times
BioVie (BIVI) Advances Parkinson's Trial with Innovative Drug Be - GuruFocus
BioVie (BIVI) Advances Key Drug Treatments and Clinical Trials - GuruFocus
BioVie Unveils Corporate Advisory Board Featuring Neuralink - GlobeNewswire
BioVie Inc. Announces Formation of Corporate Advisory Board - marketscreener.com
BioVie (BIVI) Advances Parkinson's Trial with Innovative Drug Bezisterim - GuruFocus
Geode Capital Management LLC Buys 85,234 Shares of BioVie Inc. (NASDAQ:BIVI) - Defense World
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):